Tp-e间期，Tp-e/QT与ICD一级预防患者发生恶性室性心律失常的关系

目的：探讨心电图T波峰末间期（Tp-e）及T波峰末间期与QT间期的比值（Tp-e/QT）与ICD一级预防患者发生恶性室性心律失常的关系。方法分析我院2011年3月~2014年2月因严重慢性心功能不全（左室射血分数≤35%,纽约心功能分级为Ⅱ/Ⅲ级,且既往从未发生过室速或室颤等恶性心律失常）接受ICD（植入式心脏复律除颤器）一级预防的患者68例,对所有的患者随访18~38个月（平均26个月）。在随访过程中,患者根据是否发生终点事件分为高危组及低危组;本研究以SCD或室颤、室速作为终点事件。术前对所有的患者进行12导联心电图、心脏彩超、24 h动态心电图等检查,并分析Tpeak-Tend间期及（Tpeak-Tend）/QT。结果随访过程中,因ICD识别持续性室速或室颤而引发恰当放电的患者共11例,由ICD发现非持续性室速而不需治疗的患者共7例,故高危组患者共18例。从未发生室速或室颤者共50例为低危组。高危组患者的（Tp-e）105±15 ms明显高于低危组90±17 ms（P=0.003）;（Tpeak-Tend）/QT比值在高危组与低危早组相比有明显的统计学差异（0.27±0.04 vs 0.22±0.05,P=0.002）. TpTe/QT≥0.255预测ICD一级预防患者发生恶性室性心律失常风险的敏感性和特异性分别为72.2%和65.9%;TpTe≥103 ms预测ICD一级预防患者发生恶性室性心律失常风险的敏感性和特异性分别为66.7%和67.9%。结论 Tp-e间期、Tp-e/QT比值与ICD一级预防患者发生恶性室性心律失常的关系密切,Tpeak-Tend间期及Tp-e/QT比值越大,ICD一级预防患者发生恶性室性心律失常如室速、室颤的可能性越大。     

Experience on application of transveneous implantable MINI Ⅱ cardioverterdefibrillator for ventricular tachycardia due to right ventricular dysplasia:a report of a case

Theimplantablecardioverterdefibrillator(ICD)therapyhasbecomeanimportantmethodfortreatingmalignantventrlculartachyarrhythmiasatpresent.ThisreportdealswithourPrimaryexperienceinclinicalapplicationoftransveneousimplantablecardioverterdeflbrlllator.CLINICALMATERIALSA43--year--oldmalepatientadmittedtohospitalonoctober10.1997becauseofparoxymalventrlculartachycardla(VT).HecomplainedofsufferingVTasmanyas6timesduring2years.TherateofVTwas110to180bpm.In:3times.V'YcouldnotbeterminatedbyInject…     

Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia

Background Implantable cardioverter defibrillator （ICD） is the only effective therapy in patients with life threatening ventricular arrhythmias. Inappropriate detection and therapy by ICDs are the most common causes of side effects that affect the quality of life in ICD recipients. This study evaluated the incidence and causes of inappropriate detection and therapy by ICDs in patients in our hospital. Methods From January 2000 to December 2005, fifty patients who received ICD implantation for ventricular arrhythmias for prevention of sudden cardiac death were evaluated in this study. Each ICD was programmed using clinical arrhythmic and cardiac data of the patient before discharge. Patients were followed up by standard schedule after implantation and all data retrieved from each device were collected and saved for further analysis. Results No arrhythmic event was detected in 12/50 （24%） patients during the period of follow-up. Among the remaining patients, 11 （22%） experienced inappropriate detections and therapies during follow-up in this study. ICD detected 383 ventricular tachyarrhythmia （VT） and 108 ventricular fibrillation （VF） episodes and delivered 678 therapies. In VT group, ICD delivered 413 antitachycardiac pacings （ATPs） and 118 shocks, among which 78 ATPs and 9 shocks were initiated by 55/383 （14.3%） inappropriate detections. In VF group ICD delivered 147 shocks, among which 56 shocks were initiated by 28/108 （26.9%） inappropriate detections. Overall, more than 50% of these episodes were caused by atrial fibrillation （AF） with rapid ventricular response, followed by electromagnetic or myopotential interference. In addition, most inappropriate therapies occurred within one year after ICD implantation. Conclusions About one fifth of patients experienced ICD inappropriate detection and therapy after implantation. The main cause was AF with rapid ventricular response, followed by electromagnetic or myopotential interference.     

右室流出道起搏与右室心尖起搏QRS波对比研究

目的评估右室间隔部起搏与右室心尖起搏的效果。方法将96例起搏器植入患者分为右室心尖起搏组（58例）与右室流出道间隔起搏组（38例）,其中流出道间隔起搏组又分为高位间隔组（25例）和低位间隔组（13例）。测量各组术前、术后完全起搏的QRS时限（QRSd）、术后完全起搏的QRSd与术前QRSd的差值（ΔQRSd）。结果右室流出道间隔起搏组完全起搏时QRSd短于右室心尖起搏组[（139±8.6）ms vs（156±15.4）ms,P〈0.001],右室流出道间隔起搏组ΔQRSd〈右室心尖起搏组[（39±10.9）ms vs（57±13.2）ms,P〈0.001]。高位间隔组与低位间隔组术后、术前QRSd、ΔQRSd均无统计学差异（P〉0.05）。结论右室流出道间隔部起搏比右室心尖起搏更接近生理性起搏。     

冠心病患者QT间期离散度与程序刺激诱发的室性心动过速相关性研究

目的 :探讨体表心电图QT间期离散度与冠心病患者程序刺激诱发的室性心动过速的关系。方法 :选择 4 0例接受心脏导管手术的患者 ,其中陈旧性心肌梗死患者 2 0例 ,阵发性室上性心动过速患者 2 0例。术前测定患者体表心电图QT间期离散度 ,术中在右心室起搏刺激以诱发持续室性心动过速 ,探讨QT间期离散度与室性心律失常之间的关系。结果 :2 0例陈旧性心肌梗死患者共有 6例诱发出持续室性心动过速 ,2 0例阵发性室上性心动过速患者中无 1例诱发出持续室性心动过速。冠心病患者体表心电图QT间期离散度较阵发性室上速患者明显增大 (85 .7± 2 4 .6msvs 34.8± 11.3ms,P <0 .0 1) ;冠心病患者中诱发出持续室性心动过速者 ,其QT间期离散度较未诱发出持续室性心动过速者亦明显增大 (98.7± 5 6 .2msvs 70 .4± 2 8.5ms,P <0 .0 5 )。取QT间期离散度≥ 110ms,对室性心律失常的预测有一定价值。结论 :体表心电图QT间期离散度与冠心病患者室性心律失常具有相关性 ,取QTd≥ 110ms对室性心律失常有一定的预测价值。     

维拉帕米敏感性室性心动过速的射频消融术治疗

目的 探讨射频消融术治疗维拉帕米敏感性室性心动过速（室速）的有效性和安全性。方法 选择本院18例确诊为维拉帕米敏感性室速的患者为研究对象。入院后行相关检查排除器质性心脏病后接受射频消融术。术中寻找Purkinje电位（P电位）,标测到P电位较体表的QRS波提前≥20 ms为理想消融靶点。在25 ～35 W,60℃左右的设置下行消融。其周围位置在同样的设置下消融。达到消融终点后,行右心室刺激或者异丙肾上腺素静滴后再行右心室刺激检验消融效果。术后给予常规治疗及护理。出院后随访3～6个月。结果 18例患者中,17例起源左后分支,1例起源左前分支,室速,分别在左中后间隔及前间隔消融成功。术中全部达到消融终点,均未再能诱发室速。理想靶点的P电位较体表QRS波提前(24.0±3.5)ms。发现提前越多,消融所需时间越少。术后有2例患者出现穿刺口血肿,无其他并发症出现。随访3～6个月,有2例多次心动过速发作,发作性质及心电图同前。治愈率达88.9％。结论 射频消融手术治疗维拉帕米敏感性室速是安全有效的,可以达到根治的目的,但有一定的复发率。     

China＇s quality watchdog： Latest tests show infant formula milk safe

Background Radiofrequency catheter ablation （RFCA） has been established as an effective and curative therapy for ventricular tachycardia （VT） and severely symptomatic premature ventricular contraction （PVC） from the outflow tract in structurally normal hearts. This study aimed to investigate electrophysiologic characteristics and effects of RFCA for patients with idiopathic VT and symptomatic PVC originating from the valve annulus. Methods Characteristics of body surface electrocardiogram （ECG） and endocardiogram in a successful RFCA target were analyzed in 16 patients with idiopathic VT and symptomatic PVC originating from the valve annulus. Additionally, the ECG characteristics of VT or PVC were compared with those of manifest Wolff-Parkinson-White （WPW） syndrome originating from the same site of origin in 15 patients. Results Thirteen patients were successful, 2 recurrent and 1 failed. The recurrent cases underwent successful ablation the second time guided by the Ensite 3000 mapping system. In all patients with the WPW syndrome, the characteristics of QRS morphology were well matched with those of the VT and PVC that originated from corresponding sites of origin. Conclusions RFCA is an effective curative therapy for VT and There are specific characteristics in ECG and the ablation site accessory pathway＇s algorithm. symptomatic PVC originating from the valve annulus. could be located by means of the WPW syndrome     

埋藏式心内除颤器应用4例报告

对４名器质性心脏病继发顽固、重症室性心动过速和／或心室纤颤（ＶＴ／Ｖｆ）患者采用埋藏式心内除颤器治疗,得左锁骨下静脉穿刺。将ＩＣＤ心内三级导管引入右室心尖部。将ＩＣＤ埋入左上胸囊袋,借助程控电脑诱发ＶＴ／Ｖｆ,确认ＩＣＤ确能有效感知和终上ＶＴ／Ｖｆ后缝合切口。结果：４例患者平均随访７月,均未再发晕厥,共发生ＶＴ１９次。均被ＩＣＤ在１１ｓ内成功终止,未发生与ＩＣＤ相关的并发症,结果表明：ＩＣＤ的疗效     

索他洛尔对射频消融患者QTd的影响

目的 :观察索他洛尔对房室旁道射频消融 (RFCA )患者 QT离散度 (QTd)及电生理作用的影响 ,对药物在术中应用的安全性作评估。 方法 :36例房室折返性心动过速 (AVRT)接受 RFCA的患者 ,随机分为对照组 (18例 ,单纯行 RFCA)和药物组 (18例 ,RFCA+顿服索他洛尔 16 0 m g)。药物组服药后每 30 min测量 1次电生理参数 ,观察 2 .5 h。两组在术前、术后分别测量 QTd。 结果 :两组术前 QTd无差异 ,对照组术前、术后 QTd无明显变化。药物组服药后 ,电生理参数与服药前比较相差显著 ,RFCA术前、术后 QTd分别为 (30 .9± 14.3)和 (2 4.7± 9.6 ) m s;QTcd分别为 (33.7± 17.1)和 (2 5 .2± 10 .1) m s;QTL cd分别为 (30 .8± 14.1)和 (2 5 .6± 19.4) m s,3项参数均 P<0 .0 5。两组术后比较 QTd,QTcd,QTL cd均有显著差异。结论 :索他洛尔可轻度降低 QTd,致心律失常的危险性较低 ,无器质性病变的 RFCA患者术中应用可帮助终止心动过速频繁发作 ,安全有效     

心律转复除颤器植入术中避免常规 除颤阈值测试的随访观察

目的：探讨心律转复除颤器（ICD）和心室再同步心脏转复除颤器（CRT-D）植入术中未进行除颤阈值测试的患者,治疗恶性室性心律失常的有效性和安全性。方法：收集1999年10月至2008年8月间ICD植入术中未进行除颤阈值测试的21例ICD/CRT-D患者临床资料,应用体外程控仪获取存取信息并结合随访资料进行分析。结果：17例室性心动过速（室速）或心室颤动（室颤）患者植入ICD,4例心肌病合并严重心力衰竭患者植入CRT-D,术中均未进行除颤阈值测试。8例术后1周进行除颤阈值测试,其中3例（37.5%）未诱发出室速/室颤。程控随访1~7(4.2±1.9)年,21例未进行除颤阈值测试的患者中16例记录到室速或室颤事件,ICD成功除颤89阵（成功率100%）,抗心动过速起搏（ATP）终止室速120阵次（成功率51.1%）,低能量同步转复22阵次（成功率59.2%）。术后大多数患者联合应用抗心律失常药物,无恶性室性心律失常相关死亡病例。结论：ICD/CRT-D植入术中不常规进行除颤阈值测试可避免相关并发症发生,术后随访可有效治疗恶性室性心律失常,预防心脏性猝死。     

Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation

Background Ventricular tachycardia （VT） and ventricular fibrillation are the main reasons causing sudden cardiac death.This study aimed to investigate the effects of nifekalant hydrochloride （NIF） on QT dispersion （QTd） in treating VT.Methods A total of 16 consecutive patients suffered sustained VT was included and then randomly divided into two groups according to the administration duration of NIF.In long-time group （group L）, patients were injected with NIF continuously for at least 12 hours after a bolus dose.The patients in short-time group （group S） were injected with NIF just for 1 hour.Results There were 7 of all 10 episodes of VT which were terminated by NIF, including 4 episodes in group L were stopped over 1 hour after continuous infusion of NIF.One patient suffered from torsade de pointes.Electrocardiography analysis indicated that QTd was significantly decreased 12 hours after stopping of infusing NIF compared with that when VT stopped （（45.4±22.1） ms vs.（73.4±33.2） ms, P 〈0.01）, and the corrected QTd （QTcd） decreased too （（47.8±22.9） ms vs.（78.3±36.5） ms, P 〈0.01 ）.There was a positive correlation between the increase in QTd and dose of administrating NIF （P 〈0.01）, so was QTcd （P 〈0.01）.Conclusions More administration of NIF indicates higher terminating rate of VT and more QTd prolongation.However,the safety is acceptable if several important issues were noticed in using NIF, such as serum potassium concentration,stopping side-effect related agents, and carefully observing clinical responses.     

射频消融治疗心室流出道特发性室性心律失常的临床评价

目的探讨射频消融治疗心室流出道特发性室性心动过速（VT）和室性早搏（PVC）的临床效果、心电图及电生理特征。方法采用起搏标测、激动标测和非接触标测的方法对105例心室流出道室性心律失常的患者进行射频消融治疗,其中男42例,女63例,年龄47±16（12—73）岁。VT27例,PVC78例。结果（1）105例患者中97例成功,8例失败,成功率93．3％。15例复发,复发者再次消融后成功。（2）起源于右室流出道84例,左室流出道21例。其中起源于主动脉瓣上Valsalva左冠窦16例,主动脉瓣下左室流出道心内膜2例,主动脉瓣与二尖瓣环纤维连接处3例。（3）术中出现1例急性心包压塞,2例少量心包积液。结论射频导管消融治疗心室流出道特发性室性心律失常是一种安全、有效的方法。     

心大静脉不同部位室性心律失常的心电图特征及射频导管消融治疗

目的 探讨心大静脉（GCV）不同部位室性期前收缩（PVCs）和室性心动过速（VT）的心电图特征及射频导管消融治疗的疗效与安全性.方法 4例经GCV标测和消融患者,其中持续及短阵性VT各1例,PVCs2例.经左、右心室流出道（LVOT、RVOT）及二尖瓣环心内膜标测与试消融无效各2例,最后均经GCV标测与消融,并对GCV远端（前室间静脉分支前-二尖瓣环前壁心外膜）及最远端（前室间静脉分支后-LVOT）消融成功者的心电图特征进行分析.结果 首次均采用普通温控导管仅1例消融成功,因阻抗太高无法放电失败3例,其中2例再次经三维标测系统EnSite3000-NavX指导下,采用盐水灌注导管标测与消融均成功,1例放弃再次消融,成功率75.00%.经GCV远端及最远端消融成功各1及2例.激动顺序标测有效靶点心内电图较体表心电图QRS波群起始点提早（36.00±2.65）ms,可见A波及V波（V＞A） 起搏标测的QRS波群与自发PVCs/VT形态12及11导联相同各2例.GCV远端及最远端消融成功者体表12导联心电图特征不同：（1）前者假性＂δ＂波时间≥75ms而后者＜75ms （2）前者V1呈R型无S波群而V4～V6有S波（呈Rs型）,后者则相反.结论 部分体表心电图特征符合LVOT或二尖瓣环前壁起源的PVCs/VT,经上述部位标测与消融无效者,应考虑经GCV采用盐水灌注导管进行标测与消融,且安全有效.     

特发性室性心动过速及室性早搏的射频消融治疗

目的：探讨特发性室性心动过速（IVT）的射频消融（RFCA）治疗效果。方法：对3例左室特发性室速（ILVT）、2例右室流出道室速（RVOT）及3例右室流出道室性早搏，分别采用激动顺序标测法及起搏标测法行射频消融治疗。结果：所有患者术中均成功消融室速或室早，术后随访3个月－2年，无一例复发。结论：射频消融治疗特发性室速或室早是安全、有效且成功率高的一种方法。     

植入心律转复除颤器患者室性心律失常和放电事件的相关分析

【目的】 分析植入心律转复除颤器(ICD)患者在一级或二级预防中发生室性心律失常和放电治疗情况及相关因素。 【方法】 对2004年3月至2012年9月在中山大学附属第一医院植入了ICD的92例患者进行程控随访,结合患者的临床资料进行回顾性分析。【结果】 92例患者,其中ICD一级预防45例,二级预防47例,共进行了423人次的程控随访,平均随访时间(27.6 ± 21.8)个月。有37.8%的一级预防患者出现了室速/室颤(VT/VF),平均2.53次/人年;28.9%的患者给予了放电治疗,平均0.44次/人年。在二级预防中有59.6%的患者出现VT/VF,平均4.99次/人年,其中有47.9%需要放电治疗,平均为1.41次/人年。所有患者中,有46例ICD发生放电(50.0%),其中恰当放电的35例(38.0%),不恰当放电的11例(12.0%)。总计放电334次,其中恰当的放电治疗198次(59.3%),不恰当的放电治疗136次(40.7%)。不恰当放电原因包括:房颤92次(67.6%),阵发性室上性心动过速32次(23.5%),ICD异常感知12次(8.8%)。有房颤病史的患者发生VT/VF的概率以及误放电的概率均高于无房颤病史的患者,差异有统计学意义(P < 0.05)。【结论】 ICD在心脏性猝死的一级预防能给患者带来获益;房颤既是ICD不恰当放电的主要原因,也是提示VT/VF高发的指标。     

右心室心尖起搏伴心力衰竭患者升级心脏再同步化治疗的临床观察

目的 观察分析升级心脏再同步化治疗(CRT)对右心室心尖起搏伴心力衰竭患者的临床疗效.方法 对10例右心室心尖起搏伴心力衰竭,左心室射血分数(EF)≤35%的患者更换三腔起搏器,观察术后12个月患者的临床症状,并于术后6、12个月行超声检查,对心功能相关指标进行统计学分析.结果 术后12个月死亡2例,临床症状改善7例,存活的8例患者平均心功能NYHA分级提高,B型利钠肽下降[(184±73)ng/L比(545±286)ng/L],左房直径缩小[(43±5)mm比(46±7)mm],肺动脉压力下降[(42±6)mm Hg比(54±13)mm Hg],平均左心室EF提高[(32±4)%比(35±5)%],组织多普勒显示12节段达峰时间最大差[(136±28)比(97±18)ms]和室间收缩时间差[(52±5)ms比(31±6)ms)]均有改善(均P＜0.05).结论 CRT能改善右心室心尖起搏合并心力衰竭患者的症状和NYHA心功能分级,对于右心室心尖起搏发生心力衰竭的患者,CRT是可靠的治疗手段.

Abstract：

Objective To investigate the clinical efficacy of cardiac resynchronization therapy (CRT) through biventricular pacing in chronically right ventricular apical paced patients with heart failure. Methods Ten chronically right ventricular apical paced patients with left ventricular ejection fraction (EF)≤35% underwent CRT upgrading. And the follow-up period was over 12 months. Seven of them reported a significant improvement in their symptoms. Two patients died and one patient had no response. As compared with pre-CRT, CRT significantly improved NYHA classification, decreased left atrium diameter [(43 ±5) mm vs (46 ±7) mm], pulmonary arterial pressure [(42 ±6) mm Hg vs (54 ±13 ) nnn Hg] and BNP [( 184 ± 73 ) ng/L vs ( 545 ± 286 ) ng/L] ( P ＜ 0. 05 ), improved left ventricular EF [(35 ± 5 ) % vs ( 32 ± 4 ) %]. Tissue Doppler imaging revealed the maximal difference of time to peak myocardial systolic contraction of 12 left ventricular segment shortened [(136 ± 28) ms vs (97 ± 18 )ms],interventricular mechanical delay shortened [(52 ± 5 ) ms vs (31 ± 6 ) ms)] after upgrading. Conclusion CRT upgrading from right ventricular apical pacing may improve left ventricular function in patients with heart failure.     

Radiofrequency catheter ablation at the left coronary cusp in treatment of repetitive monomorphic tachycardia of the left ventricular outflow tract

Background The aim of this study was to clarify the electrocardiographic characteristics of repetitive monomorphic ventricular tachycardia (RMVT) originating from the left ventricular outflow tract, and to describe the results of treatment with radiofrequency catheter ablation (RFCA).Methods Routine 12-lead surface electrocardiography and electrophysiological studies were performed on 11 RMVT patients with no organic heart disease, who were subsequently treated with RFCA directed at targets identified by pace mapping.Results The surface electrocardiogram QRS characteristics of RMVT included an atypical left bundle branch block and right axis deviation, with a low amplitude “rs” or “rS” pattern in lead Ⅰ, an “rS” or “RS” pattern in V1, and a precordial R wave transition zone in V2 or V3. In 1 patient, a small S wave was observed in V5. Using pace mapping techniques, we selected the left coronary cusp as the ablation target. RMVT was eliminated in all 11 patients immediately after radiofrequency energy delivered. During a follow-up of 13±7 months, RMVT recurred in only 1 patient. Conclusion RMVT originating from the left ventricular outflow tract has specific electrocardiographic characteristics, and can be successfully and safely cured using RFCA directed at the left coronary cusp.     

ICD应用临床分析

目的报告50例植入型心律转复除颤器(ICD)的临床应用观察.方法对我院1998年5月至2005年11月植入的45例,另有5例更换ICD的患者的临床应用进行观察(3~90个月).结果7例患者死亡,其余43例发生千次以上严重心律失常均由ICD成功终止.结论ICD手术过程安全,术后要密切随访,及时调整工作参数,即可达到较好防治严重心律失常降低猝死的疗效.     

单导管射频消融治疗主肺动脉干室性早搏／室性心动过速临床观察

目的探讨起源于主肺动脉干（MSPA）室性早搏（PVCs）/室性心动过速（VT）的心电图特征、标测方法及单导管射频消融治疗的疗效与安全性。方法选取经肺动脉造影证实起源于MSPA的PVCs／VT患者12例（MSPA组）以及右心室流出道（RVOT）前间隔起源的PVCs／VT患者59例（RVOT组）,均采用单导管常规标测技术进行标测、消融。比较分析两组患者心电图特征,随访MSPA组患者的疗效。结果MSPA组患者体表心电图具有下壁导联R波振幅高以及胸前导联移形较早（多位于V2～V3）的特点,其有效靶点高电压（8V）可起搏心室,并与自发PVCs/VT的QRS波形12导联完全相同,有效靶点心室电位较PVCs／VT体表心电图QRS波起始点提早（33.91±3.69）ms,10例可记录到远场A、V波,6例可记录到融合或分离的尖峰或碎裂电位。所有消融治疗均成功,无并发症发生,随访期间无复发病例。结论起源于MSPA的PVCs／VT并非罕见．单导管标测及消融安全、有效．     

零射线下导管射频消融治疗特发性主动脉窦内室性早搏

目的通过比较在CARTO3指导下零射线与常规在X线指导下对特发性主动脉窦内室性早搏（ASC-PVCs）导管射频消融 来评价其治疗安全性、有效性及可行性。方法分析2013年4月~2015年10月于南方医院因特发性主动脉窦内室早行射频消融 （RFCA）治疗的患者52例,其中零射线组23例,即运用Carto3系统重建主动脉窦三维模型后在零射线下行导管消融。另29例 在X线下常规标测和消融,为常规消融组。比较两组的靶点标测时间、总放电次数、手术即时成功率、手术总时间、X线曝光时 间、随访观察疗效（复发率）及并发症。结果零射线组手术即时成功率看似高于常规组,但两组患者即时成功率差异无统计学意 义［22/23（96%）vs 24/29（83%）,P=0.21］;两组患者术中均无并发症发生。与常规组相比,零射线组靶点标测时间明显缩短 （4.3±1.7 vs 7.8±2.6 min,P<0.01）,零射线组与常规组手术总时间差异无统计学意义（79.6±8.8 vs 77.4±7.2 min,P=0.332）。与零 射线组比较,常规组放电次数明显较多（7.9±3.2 vs 4.8±1.1,P<0.01）,零射线组整个手术过程完全零射线,而常规组X线曝光时 间为23.1±6 min,随访5~20个月,常规组复发4例,零射线组1例复发。结论CARTO3指导下零射线导管射频消融治疗特发性 主动脉窦频发室性期前收缩是一种安全、有效、可行的方法。CARTO3指导零射线射频消融相对常规消融方法;其靶点标测时 间缩短、总放电次数减少且不延长手术总时间,而且全手术过程为零射线。